These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24445732)

  • 21. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures.
    Schousboe JT; Dowd BE; Davison ML; Kane RL
    Osteoporos Int; 2010 Nov; 21(11):1899-909. PubMed ID: 19967337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence.
    Hansen C; Pedersen BD; Konradsen H; Abrahamsen B
    Osteoporos Int; 2013 Jul; 24(7):2079-97. PubMed ID: 23179576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial.
    McAlister FA; Ye C; Beaupre LA; Rowe BH; Johnson JA; Bellerose D; Hassan I; Majumdar SR
    Osteoporos Int; 2019 Jan; 30(1):127-134. PubMed ID: 30232538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary prevention of osteoporotic fractures--an "OPTIMAL" model of care from Singapore.
    Chandran M; Tan MZ; Cheen M; Tan SB; Leong M; Lau TC
    Osteoporos Int; 2013 Nov; 24(11):2809-17. PubMed ID: 23615816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher rates of osteoporosis treatment initiation and persistence in patients with newly diagnosed vertebral fracture when introduced in inpatients than later in outpatients.
    Spechbach H; Fabreguet I; Saule E; Hars M; Stirnemann J; Ferrari S; Rizzoli R; Chevalley T
    Osteoporos Int; 2019 Jul; 30(7):1353-1362. PubMed ID: 30820609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary prevention of osteoporotic fractures: evaluation of the Amiens University Hospital's fracture liaison service between January 2010 and December 2011.
    Dehamchia-Rehailia N; Ursu D; Henry-Desailly I; Fardellone P; Paccou J
    Osteoporos Int; 2014 Oct; 25(10):2409-16. PubMed ID: 24980182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term persistence with anti-osteoporosis drugs after fracture.
    Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
    Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
    Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
    Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fracture liaison service model: treatment persistence 5 years later.
    Naranjo A; Molina A; Quevedo A; Rubiño FJ; Sánchez-Alonso F; Rodríguez-Lozano C; Ojeda S
    Arch Osteoporos; 2021 Apr; 16(1):60. PubMed ID: 33813663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
    Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
    Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compliance to The Joint Commission proposed Core Measure set on osteoporosis-associated fracture: review of different secondary fracture prevention programs in an open medical system from 2010 to 2015.
    Fojas MC; Southerland LT; Phieffer LS; Stephens JA; Srivastava T; Ing SW
    Arch Osteoporos; 2017 Dec; 12(1):16. PubMed ID: 28155141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment for older men with fractures.
    Shepherd AJ; Cass AR; Ray LA; Tan A; Wilkinson GS
    Osteoporos Int; 2012 Mar; 23(3):1041-51. PubMed ID: 21811867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA.
    Asche C; Nelson R; McAdam-Marx C; Jhaveri M; Ye X
    Osteoporos Int; 2010 Aug; 21(8):1427-36. PubMed ID: 19798459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
    Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
    Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.
    Sakai A; Ikeda S; Okimoto N; Matsumoto H; Teshima K; Okazaki Y; Fukuda F; Arita S; Tsurukami H; Nagashima M; Yoshioka T
    Osteoporos Int; 2014 Sep; 25(9):2245-53. PubMed ID: 24899103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for fracture among current, persistent users of bisphosphonates.
    LeBlanc ES; Rosales AG; Balasubramanian A; O'Malley CD; Egbuna O; Friess D; Perrin NA
    Osteoporos Int; 2015 Feb; 26(2):713-25. PubMed ID: 25354654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
    Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
    Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.